| Q34377086 | "Deconstruction" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. |
| Q39644366 | 'Second-generation' mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function |
| Q92575706 | 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors |
| Q34115248 | 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry |
| Q41340398 | 3,4-Methylenedioxypyrovalerone (MDPV)-induced conditioned taste avoidance in the F344/N and LEW rat strains |
| Q34459984 | 3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter |
| Q36441681 | 4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry |
| Q39409276 | A case of fatal idiosyncratic reaction to the designer drug 3,4-methylenedioxypyrovalerone (MDPV) and review of the literature |
| Q42771936 | A combined approach using transporter-flux assays and mass spectrometry to examine psychostimulant street drugs of unknown content |
| Q90703148 | A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics |
| Q38120432 | Abuse liability of novel 'legal high' designer stimulants: evidence from animal models |
| Q37424592 | Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats |
| Q34507647 | Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats |
| Q39107792 | Active vaccination attenuates the psychostimulant effects of α-PVP and MDPV in rats |
| Q89161244 | Acute Intoxications Involving α-Pyrrolidinobutiophenone (α-PBP): Results from the Swedish STRIDA Project |
| Q35749136 | Acute Methylenedioxypyrovalerone Toxicity. |
| Q37685951 | Age-dependent MDPV-induced taste aversions and thermoregulation in adolescent and adult rats |
| Q28087404 | Agonist Medications for the Treatment of Cocaine Use Disorder |
| Q41580706 | Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters |
| Q34484408 | Amphetamine activates calcium channels through dopamine transporter-mediated depolarization. |
| Q92069529 | Amphetamine and the Smart Drug 3,4-Methylenedioxypyrovalerone (MDPV) Induce Generalization of Fear Memory in Rats |
| Q88498651 | Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats |
| Q35853599 | Amphetamines, new psychoactive drugs and the monoamine transporter cycle. |
| Q41340468 | An assessment of MDPV-induced place preference in adult Sprague-Dawley rats |
| Q60265087 | Analytical quantification, intoxication case series, and pharmacological mechanism of action for N -ethylnorpentylone (N -ethylpentylone or ephylone) |
| Q39057330 | Application of a Combined Approach to Identify New Psychoactive Street Drugs and Decipher Their Mechanisms at Monoamine Transporters. |
| Q38978095 | Atypical dopamine efflux caused by 3,4-methylenedioxypyrovalerone (MDPV) via the human dopamine transporter. |
| Q36976755 | Awash in a sea of 'bath salts': implications for biomedical research and public health |
| Q37540813 | Bath salts and synthetic cathinones: an emerging designer drug phenomenon |
| Q34491601 | Baths salts, spice, and related designer drugs: the science behind the headlines |
| Q91862230 | Behavioral economic analysis of the reinforcing effects of "bath salts" mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats |
| Q34385074 | Behavioral pharmacology of designer cathinones: a review of the preclinical literature |
| Q53824147 | Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat. |
| Q36432395 | Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters |
| Q27324932 | Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats |
| Q89126816 | Binge-like acquisition of α-pyrrolidinopentiophenone (α-PVP) self-administration in female rats |
| Q38430705 | Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine |
| Q26828641 | Cathinone neurotoxicity ("The "3Ms") |
| Q47433947 | Changes in CREB and deltaFosB are associated with the behavioural sensitization induced by methylenedioxypyrovalerone. |
| Q50435387 | Characterization of the discriminative stimulus effects of 3,4-methylenedioxypyrovalerone in male Sprague-Dawley rats |
| Q51738919 | Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats. |
| Q47700327 | Chiral Resolution and Enantioselectivity of Synthetic Cathinones: A Brief Review. |
| Q50848310 | Chiral determination of 3,4-methylenedioxypyrovalerone enantiomers in rat serum. |
| Q41299806 | Chiral resolution and absolute configuration of the enantiomers of the psychoactive "designer drug" 3,4-methylenedioxypyrovalerone. |
| Q58112081 | Cognitive deficits and neurotoxicity induced by synthetic cathinones: is there a role for neuroinflammation? |
| Q38788193 | Comparing rewarding and reinforcing properties between 'bath salt' 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats. |
| Q40647058 | Concentrations of MDPV in rat striatum correlate with the psychostimulant effect. |
| Q50442676 | Conditioned taste avoidance, conditioned place preference and hyperthermia induced by the second generation 'bath salt' α-pyrrolidinopentiophenone (α-PVP). |
| Q90562135 | Contribution of monoaminergic mechanisms to the discriminative stimulus effects of 3,4-methylenedioxypyrovalerone (MDPV) in Sprague-Dawley rats |
| Q89208058 | Cytotoxic Effects of 3,4-Catechol-PV (One Major MDPV Metabolite) on Human Dopaminergic SH-SY5Y Cells |
| Q53687526 | DARK Classics in Chemical Neuroscience: Cathinone-Derived Psychostimulants. |
| Q45053192 | Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release. |
| Q37237463 | Designer Drugs: A Synthetic Catastrophe |
| Q30300017 | Designer drugs 2015: assessment and management |
| Q36510321 | Differential effects of 3,4-methylenedioxypyrovalerone (MDPV) and 4-methylmethcathinone (mephedrone) in rats trained to discriminate MDMA or a d-amphetamine + MDMA mixture |
| Q40006791 | Differentiation of cyclic tertiary amine cathinone derivatives by product ion electron ionization mass spectrometry |
| Q37279059 | Discriminative Stimulus Effects of Binary Drug Mixtures: Studies with Cocaine, MDPV, and Caffeine |
| Q52621335 | Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats. |
| Q28539324 | Dose and time-dependent selective neurotoxicity induced by mephedrone in mice |
| Q39714625 | Editor's Highlight: Characterization of Hepatotoxicity Mechanisms Triggered by Designer Cathinone Drugs (β-Keto Amphetamines). |
| Q54478343 | Effects of D1 and D2 receptor antagonists on the discriminative stimulus effects of methylendioxypyrovalerone and mephedrone in male Sprague-Dawley rats trained to discriminate D-amphetamine. |
| Q57031630 | Effects of MDPV on dopamine transporter regulation in male rats. Comparison with cocaine |
| Q38680967 | Effects of ceftriaxone on conditioned nicotine reward in rats |
| Q47903083 | Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice |
| Q27311250 | Effects of social interaction and warm ambient temperature on brain hyperthermia induced by the designer drugs methylone and MDPV. |
| Q34656885 | Effects of the neuropeptide S receptor antagonist RTI-118 on abuse-related facilitation of intracranial self-stimulation produced by cocaine and methylenedioxypyrovalerone (MDPV) in rats |
| Q38966221 | Electrophysiological Actions of Synthetic Cathinones on Monoamine Transporters |
| Q37008883 | Enhanced Dopamine Release by Dopamine Transport Inhibitors Described by a Restricted Diffusion Model and Fast-Scan Cyclic Voltammetry. |
| Q37705731 | Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates |
| Q50452744 | Exposure of adolescent mice to 3,4-methylenedioxypyrovalerone increases the psychostimulant, rewarding and reinforcing effects of cocaine in adulthood |
| Q48380075 | Fatal Intoxication with α-PVP, a Synthetic Cathinone Derivative |
| Q39761680 | First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry |
| Q48028433 | Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family |
| Q88578159 | Functional connectivity, behavioral and dopaminergic alterations 24 hours following acute exposure to synthetic bath salt drug methylenedioxypyrovalerone |
| Q46478793 | GC-MS, MS/MS and GC-IR Analysis of a Series of Methylenedioxyphenyl-Aminoketones: Precursors, Ring Regioisomers and Side-Chain Homologs of 3,4-Methylenedioxypyrovalerone |
| Q49829719 | Gestational Exposure to the Synthetic Cathinone Methylenedioxypyrovalerone Results in Reduced Maternal Care and Behavioral Alterations in Mouse Pups |
| Q50453374 | Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG). |
| Q89736093 | Hazard Characterization of Synthetic Cathinones Using Viability, Monoamine Reuptake, and Neuronal Activity Assays |
| Q89655812 | How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe |
| Q55059127 | In vitro Phase I and Phase II metabolism of α-pyrrolidinovalerophenone (α-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol. |
| Q34504512 | In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant |
| Q30535782 | In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity |
| Q35889508 | In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats |
| Q37718575 | Individual Differences in the Relative Reinforcing Effects of 3,4-Methylenedioxypyrovalerone under Fixed and Progressive Ratio Schedules of Reinforcement in Rats |
| Q48211628 | Intended and unintended use of cathinone mixtures |
| Q39703486 | Interactions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells. |
| Q96020143 | Intoxication cases associated with the novel designer drug 3',4'-Methylenedioxy-α-pyrrolidinohexanophenone (MDPHP) and studies on its human metabolism by high-resolution mass spectrometry |
| Q40436637 | Intoxications involving MDPV in Sweden during 2010-2014: Results from the STRIDA project |
| Q33845750 | Intracranial self-stimulation to evaluate abuse potential of drugs. |
| Q30680394 | Intravenous self-administration of entactogen-class stimulants in male rats |
| Q35137747 | Intravenous self-administration of mephedrone, methylone and MDMA in female rats |
| Q34701207 | Investigation of "bath salts" use patterns within an online sample of users in the United States |
| Q57016555 | Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships |
| Q38169542 | Khat and synthetic cathinones: a review |
| Q37716055 | Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects |
| Q39699950 | Locomotor Stimulant and Rewarding Effects of Inhaling Methamphetamine, MDPV, and Mephedrone via Electronic Cigarette-Type Technology. |
| Q39345691 | MDMA, Methylone, and MDPV: Drug-Induced Brain Hyperthermia and Its Modulation by Activity State and Environment |
| Q38794041 | Mephedrone and 3,4-Methylenedioxypyrovalerone (MDPV): Synthetic Cathinones With Serious Health Implications |
| Q39208665 | Mephedrone, methylone and 3,4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice |
| Q55367903 | Metabolism of α-PHP and α-PHPP in humans and the effects of alkyl chain lengths on the metabolism of α-pyrrolidinophenone-type designer drugs. |
| Q39672218 | Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells. |
| Q36097435 | Methylenedioxypyrovalerone (MDPV) mimics cocaine in its physiological and behavioral effects but induces distinct changes in NAc glucose |
| Q46363203 | Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity. |
| Q48208182 | Monoaminergic toxicity induced by cathinone phthalimide: An in vitro study |
| Q38771797 | N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability. |
| Q50903108 | N-Bromosuccinimide promoted and base switchable one pot synthesis of α-imido and α-amino ketones from styrenes. |
| Q28276182 | NPS: Medical Consequences Associated with Their Intake |
| Q38824564 | Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP). |
| Q49568474 | Neurocognitive dysfunction following repeated binge-like self-administration of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). |
| Q38167646 | Neuropathology of substance use disorders |
| Q33566201 | Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs |
| Q58580546 | Neuropharmacology of Synthetic Cathinones |
| Q34546425 | Neurotoxicity Induced by Mephedrone: An up-to-date Review |
| Q38983638 | Neurotoxicology of Synthetic Cathinone Analogs |
| Q35117597 | Norepinephrine activates dopamine D4 receptors in the rat lateral habenula |
| Q33725088 | Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace |
| Q30251771 | Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. |
| Q49435098 | Pharmacological mechanisms underlying the cardiovascular effects of the "bath salt" constituent 3,4-methylenedioxypyrovalerone (MDPV). |
| Q34122902 | Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV). |
| Q37161370 | Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters. |
| Q39026719 | Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration |
| Q54419443 | Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective. |
| Q38887292 | Product ion tandem mass spectrometric differentiation of regioisomeric side-chain groups in cathinone derivatives |
| Q36509367 | Psychoactive "bath salts": not so soothing |
| Q41057043 | R-Modafinil exerts weak effects on spatial memory acquisition and dentate gyrus synaptic plasticity. |
| Q47836720 | Reinforcing Effects of Binary Mixtures of Common Bath Salt Constituents: Studies with 3,4-Methylenedioxypyrovalerone (MDPV), 3,4-Methylenedioxymethcathinone (Methylone), and Caffeine in Rats |
| Q38840376 | Reinforcing Effects of Cathinone NPS in the Intravenous Drug Self-Administration Paradigm |
| Q36633551 | Reinforcing and neurochemical effects of the "bath salts" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats |
| Q47869821 | Reinforcing effects of abused 'bath salts' constituents 3,4-methylenedioxypyrovalerone and α-pyrrolidinopentiophenone and their enantiomers |
| Q47796308 | Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats |
| Q50508409 | Role of hypocretin/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats. |
| Q48121252 | Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice. |
| Q64896879 | Self-administration of the synthetic cathinone MDPV enhances reward function via a nicotinic receptor dependent mechanism. |
| Q36986325 | Sensitization to the locomotor stimulant effects of "bath salt" constituents, 4-methylmethcathinone (4-MMC) and 3,4-methylenedioxypyrovalerone (MDPV), in male Sprague-Dawley rats |
| Q36977138 | Sensitization to the motor stimulant effects of 3,4-methylenedioxypyrovalerone (MDPV) and cross-sensitization to methamphetamine in rats |
| Q41299697 | Sex differences in 3,4-methylenedioxypyrovalerone (MDPV)-induced taste avoidance and place preferences. |
| Q37226593 | State-dependent and environmental modulation of brain hyperthermic effects of psychoactive drugs of abuse |
| Q30841838 | Stereoselective Actions of Methylenedioxypyrovalerone (MDPV) To Inhibit Dopamine and Norepinephrine Transporters and Facilitate Intracranial Self-Stimulation in Rats |
| Q36618734 | Stereoselective Effects of Abused "Bath Salt" Constituent 3,4-Methylenedioxypyrovalerone in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation. |
| Q37698998 | Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters. |
| Q45046796 | Structure-Activity Relationships of Synthetic Cathinones |
| Q58612229 | Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters |
| Q34537347 | Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone. |
| Q92052061 | Synthetic Cathinones: A Brief Overview of Overviews with Applications to the Forensic Sciences |
| Q39845731 | Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator |
| Q58602767 | Synthetic cathinone adulteration of illegal drugs |
| Q38850097 | Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases |
| Q38190773 | Synthetic cathinones ("bath salts"). |
| Q38710913 | Synthetic cathinones and stereochemistry: S enantiomer of mephedrone reduces anxiety- and depressant-like effects in cocaine- or MDPV-abstinent rats |
| Q34352354 | Synthetic cathinones and their rewarding and reinforcing effects in rodents |
| Q35710543 | Synthetic cathinones: a new public health problem |
| Q34385110 | Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. |
| Q38711064 | The Cathinones MDPV and α-PVP Elicit Different Behavioral and Molecular Effects Following Acute Exposure. |
| Q37078847 | The Changing Face of Recreational Drug Use. |
| Q88361885 | The Designer Drug 3-Fluoromethcathinone Induces Oxidative Stress and Activates Autophagy in HT22 Neuronal Cells |
| Q44098678 | The New Zealand new psychoactive substances regime--a step in the right direction, but questions still remain. |
| Q41879566 | The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity |
| Q92537211 | The Supplement Adulterant β-Methylphenethylamine Increases Blood Pressure by Acting at Peripheral Norepinephrine Transporters |
| Q57280193 | The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter |
| Q34493739 | The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue |
| Q49723300 | The newest cathinone derivatives as designer drugs: an analytical and toxicological review. |
| Q36926811 | The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats |
| Q47658516 | The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats |
| Q30412911 | The preclinical pharmacology of mephedrone; not just MDMA by another name. |
| Q92199145 | The synthetic cathinone psychostimulant α-PPP antagonizes serotonin 5-HT2A receptors: In vitro and in vivo evidence |
| Q57805603 | The synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates |
| Q93196767 | Using Ca2+-channel biosensors to profile amphetamines and cathinones at monoamine transporters: electro-engineering cells to detect potential new psychoactive substances |